EP4704904A1 - Agents de ciblage à base de tétrazine pour la distribution in vivo d'une charge utile - Google Patents

Agents de ciblage à base de tétrazine pour la distribution in vivo d'une charge utile

Info

Publication number
EP4704904A1
EP4704904A1 EP24727996.1A EP24727996A EP4704904A1 EP 4704904 A1 EP4704904 A1 EP 4704904A1 EP 24727996 A EP24727996 A EP 24727996A EP 4704904 A1 EP4704904 A1 EP 4704904A1
Authority
EP
European Patent Office
Prior art keywords
targeting agent
alkyl
tetrazine
independently
occurrence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24727996.1A
Other languages
German (de)
English (en)
Inventor
Jesse M. McFARLAND
Jaime R. CABRERA-PARDO
José Manuel Mejía ONETO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tambo Inc
Original Assignee
Tambo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tambo Inc filed Critical Tambo Inc
Publication of EP4704904A1 publication Critical patent/EP4704904A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/08—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de manière générale des agents de ciblage à base de tétrazine pour l'administration bio-orthogonale d'une charge utile à un emplacement ciblé chez un sujet, lesdits agents de ciblage à base de tétrazine ayant des applications, par exemple, dans le traitement du cancer, de la croissance tumorale et de l'immunothérapie.
EP24727996.1A 2023-05-04 2024-05-03 Agents de ciblage à base de tétrazine pour la distribution in vivo d'une charge utile Pending EP4704904A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363500246P 2023-05-04 2023-05-04
US202363536292P 2023-09-01 2023-09-01
PCT/US2024/027840 WO2024229427A1 (fr) 2023-05-04 2024-05-03 Agents de ciblage à base de tétrazine pour la distribution in vivo d'une charge utile

Publications (1)

Publication Number Publication Date
EP4704904A1 true EP4704904A1 (fr) 2026-03-11

Family

ID=91193742

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24727996.1A Pending EP4704904A1 (fr) 2023-05-04 2024-05-03 Agents de ciblage à base de tétrazine pour la distribution in vivo d'une charge utile

Country Status (4)

Country Link
EP (1) EP4704904A1 (fr)
JP (1) JP2026518126A (fr)
CN (1) CN121419788A (fr)
WO (1) WO2024229427A1 (fr)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR104M (fr) 1960-04-01 1961-01-09 Rhone Poulenc Sa Nouveau dérivé de la pipérazine.
US20030191291A1 (en) 2000-09-08 2003-10-09 Kochendoerfer Gerd G. Synthetic erythropoiesis stimulating proteins
EP3010486B1 (fr) 2013-06-19 2023-11-22 The Regents of The University of California Structures chimiques pour l'administration localisée d'agents thérapeutiques
EP3730154B1 (fr) 2014-02-03 2021-06-30 Eidgenössiche Technische Hochschule Zürich Conjugués de médicaments à petites molécules
AU2015229014B2 (en) 2014-03-14 2019-07-25 The Regents Of The University Of California TCO conjugates and methods for delivery of therapeutic agents
CN108135857A (zh) 2015-09-10 2018-06-08 沙思奇公司 生物正交组合物
AU2018250312C1 (en) 2017-04-07 2024-08-22 Tambo, Inc. Bioorthogonal compositions
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
WO2020077140A1 (fr) 2018-10-10 2020-04-16 Tambo, Inc. Procédés de préparation de cyclooctènes fonctionnalisés
WO2021007160A1 (fr) 2019-07-05 2021-01-14 Tambo, Inc. Agents bioorthogonaux de trans-cyclooctène et leurs utilisations dans le traitement du cancer et l'immunothérapie
TWI860386B (zh) * 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
SI4464721T1 (sl) * 2019-10-03 2025-08-29 Bicycletx Limited Heterotandemski biciklični peptidni kompleksi
JP2023537066A (ja) 2020-08-07 2023-08-30 タンボ・インコーポレイテッド トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
US20250186539A2 (en) * 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
WO2022253051A1 (fr) * 2021-06-01 2022-12-08 南京明德新药研发有限公司 Médicament conjugué à un polypeptide et son utilisation

Also Published As

Publication number Publication date
JP2026518126A (ja) 2026-06-04
WO2024229427A1 (fr) 2024-11-07
CN121419788A (zh) 2026-01-27

Similar Documents

Publication Publication Date Title
CN115990269B (zh) 依沙替康衍生物及其连接子-负载物和缀合物
CN111093708B (zh) 生物正交组合物
JP2024096335A (ja) 親水性抗体－薬物コンジュゲート
JP2025066807A (ja) 生体直交型組成物
US20250186592A1 (en) Tetrazine conjugates for in vivo targeted delivery of a payload
US20260007759A1 (en) Trans-cyclooctene prodrug of monomethyl auristatin e
JP2025525445A (ja) 抗ｒｏｒ１抗体及び抗体コンジュゲート、抗ｒｏｒ１抗体又は抗体コンジュゲートを含む組成物、並びに抗ｒｏｒ１抗体及び抗体コンジュゲートを作製及び使用する方法
WO2023077126A1 (fr) Conjugués de trans-cyclooctène
TW202132332A (zh) ＩＬ—２Ｒβγｃ結合化合物
US20250009890A1 (en) Trans-cyclooctene-modified bispecific antibodies
CN118369123A (zh) 用于有效载荷的体内靶向递送的四嗪缀合物
WO2025064427A1 (fr) Conjugués anticorps-médicament à double charge utile et leurs utilisations
WO2024229427A1 (fr) Agents de ciblage à base de tétrazine pour la distribution in vivo d'une charge utile
WO2025059685A1 (fr) Procédés d'administration ciblée in vivo d'une charge
HK40108922A (en) Tetrazine conjugates for in vivo targeted delivery of a payload
WO2024178155A1 (fr) Conjugués de trans-cyclooctène
HK40109540A (zh) 反式环辛烯缀合物
WO2024238969A1 (fr) Conjugués de dégradation de protéine ciblée modifiés par trans-cyclooctène
CA3238247C (fr) Derives d'exatecan, lieur-charge utile et leurs conjugues
US20250049936A1 (en) Bioorthogonal compositions
HK40104832A (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)